Session R.A. II 4
4 · Taysha Gene Therapies, Inc. · Filed Jan 20, 2021
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2021-01-19+199,700→ 199,700 totalExercise: $31.00Exp: 2031-01-19→ Common Stock (199,700 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.